Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)

v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
Dec. 31, 2015
Dec. 31, 2014
Concentration Risk [Line Items]    
Accounts receivable $ 203,000 $ 5,750,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B    
Concentration Risk [Line Items]    
Accounts receivable   $ 5,800,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Bristol-Myers Squibb Company    
Concentration Risk [Line Items]    
Accounts receivable $ 203,000